

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 16554-002001	Application No. 10/670,122
<b>Information Disclosure Statement</b> <b>by Applicant</b> <small>(Use several sheets if necessary)</small> <small>(37 CFR 1.98(b))</small>		<b>Applicant</b> <b>Salim Yusuf et al.</b>			
		Filing Date September 24, 2003	Group Art Unit <b>1641</b>		

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
DV	AL	01013459	01/18/89	JP (abstract only)	G01N	33/53	X	X
↓	AM	01 31052 A1	05/03/01	WIPO	C12Q	1/00	X	X
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**


Examiner Initial	Desig. ID	Document
DV	AQ	Database Internet 'Online! 2003 Cayman Chemical Inc: "519501 11 dehydro thromboxane assay" retrieved from www.caymanchem.com XP002262581 abstract.
	AR	Eikelboom et al., "Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events", Circulation 105:1650-1655, 2002, XP002262579.
	AS	Hayashi et al., "Enzyme Immunoassay of Thromboxane B <sub>2</sub> ", Biochimica et Biophysica Acta 750:322-329, 1983, XP009020472.
↓	AT	Reinke et al, "Development of an Enzyme-Linked Immunosorbent Assay of Thromboxane B <sub>2</sub> Using a Monoclonal Antibody", Prostaglandins 37:577-586, 1989, XP009020476.

Examiner Signature

Date Considered

7/1/04

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>16554-002001</b>	Application No. <b>10/670,122</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Salim Yusuf et al.</b>	
		Filing Date <b>September 24, 2003</b>	Group Art Unit <b>1641</b>

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
DV	AA	5,240,917	08/31/93	Keimowitz et al.	514	159	X
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
	AL						
	AM						
	AN						
	AO						
	AP						

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
DV	AQ	Eikelboom et al., "Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events", Circulation 105:1650-1655, 2002.
	AR	
	AS	
	AT	

Examiner Signature <i>Dan Veri</i>	Date Considered <i>7/9/04</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	